Prelude Therapeutics Inc (PRLD)

12:16 PM

Prelude Therapeutics Advances Cancer Treatment with PRT7732 Study - TipRanks

12:16 PM

Jul 23, 2025

What analysts say about Prelude Therapeutics Incorporated stockHigh-profit capital plays - Autocar Professional

Jul 23, 2025

Jul 22, 2025

Is Prelude Therapeutics Incorporated a good long term investmentGame-changing capital returns - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

Prelude Therapeutics Incorporated Stock Analysis and ForecastExplosive capital gains - jammulinksnews.com

Jul 22, 2025

Jul 19, 2025

What drives Prelude Therapeutics Incorporated stock priceDynamic profit opportunities - jammulinksnews.com

Jul 19, 2025

Jul 19, 2025

what makes prelude therapeutics incorporated stock price move sharplyFree Investment Community - Newser

Jul 19, 2025

Jul 18, 2025

Is Prelude Therapeutics Incorporated stock a good hedge against inflation10x Return With Managed Risk - Newser

Jul 18, 2025

Jul 15, 2025

What makes Prelude Therapeutics Incorporated stock price move sharplyFree Access to Investment Community - Newser

Jul 15, 2025

Jul 15, 2025

Why Prelude Therapeutics Incorporated stock attracts strong analyst attentionPro Trader Stock Focus - Newser

Jul 15, 2025

Jul 15, 2025

How Prelude Therapeutics Incorporated stock performs during market volatilityFree Smart Investment Opportunities - Newser

Jul 15, 2025

Jul 11, 2025

Prelude Therapeutics’ PRT7732 Study: A Potential Game-Changer for SMARCA4 Mutations - TipRanks

Jul 11, 2025

Jun 27, 2025

Prelude Therapeutics Advances PRT3789 in Phase 1 Study for SMARCA4 Mutant Tumors - TipRanks

Jun 27, 2025

Jun 26, 2025

Prelude Therapeutics Advances Cancer Treatment with New Phase 2 Study - TipRanks

Jun 26, 2025

Jun 23, 2025

Transcript : Prelude Therapeutics Incorporated Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 09 - MarketScreener

Jun 23, 2025

Jun 17, 2025

Baker Bros. Advisors LP Increases Stake in Prelude Therapeutics Inc. - GuruFocus

Jun 17, 2025

Jun 11, 2025

Two Sigma Investments LP Purchases 174,906 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World

Jun 11, 2025

Jun 08, 2025

Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares Acquired by Millennium Management LLC - Defense World

Jun 08, 2025

Jun 06, 2025

20,572 Shares in Prelude Therapeutics Incorporated (NASDAQ:PRLD) Purchased by BNP Paribas Financial Markets - Defense World

Jun 06, 2025

Jun 06, 2025

Two Sigma Advisers LP Raises Holdings in Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World

Jun 06, 2025

Jun 06, 2025

Phio Pharmaceuticals Advances 30-Drug Cancer Portfolio as Phase 1b Trial Shows Promise - Stock Titan

Jun 06, 2025

Jun 04, 2025

Prelude Therapeutics describes new SMARCA2 and SMARCA4 degradation inducers - BioWorld MedTech

Jun 04, 2025

Jun 04, 2025

Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares Sold by Northern Trust Corp - Defense World

Jun 04, 2025

Jun 02, 2025

Prelude Therapeutics to Present at Major Healthcare Conferences in June 2025 - MyChesCo

Jun 02, 2025

Jun 02, 2025

Prelude Therapeutics to Participate in Upcoming Healthcare Confe - GuruFocus

Jun 02, 2025

Jun 02, 2025

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences | PRLD Stock News - GuruFocus

Jun 02, 2025

Jun 02, 2025

Precision Oncology Pioneer Prelude Therapeutics Sets Stage for Major June Healthcare Conference Updates - Stock Titan

Jun 02, 2025

Jun 02, 2025

Prelude Therapeutics to Participate in Upcoming Healthcare Conferences - Yahoo Finance

Jun 02, 2025

May 28, 2025

Central Nervous System Tumors Pipeline Appears Robust With 13+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail

May 28, 2025

May 27, 2025

Prelude Therapeutics’ SWOT analysis: clinical progress buoys stock amid challenges - Investing.com India

May 27, 2025

May 22, 2025

Finance Watch: SV Closes Second Dementia Discovery Fund, Exceeding $250m Goal - insights.citeline.com

May 22, 2025

May 15, 2025

AI-powered drug development startup Pathos AI closes $365M investment - SiliconANGLE

May 15, 2025

May 15, 2025

Pathos AI secures $365M series D to fund trial of Novo Nordisk solid tumor drug - Fierce Biotech

May 15, 2025